Dr Sameer Rastogi (@samdoc_mamc) 's Twitter Profile
Dr Sameer Rastogi

@samdoc_mamc

Additional Professor, Sarcoma and GIST Medical Oncology Clinic, AIIMS, New Delhi, Passionate for the treatment of rare diseases like melanomas endocrine tumors

ID: 965280325650780160

calendar_today18-02-2018 17:42:18

804 Tweet

1,1K Takipçi

319 Takip Edilen

Dr Sameer Rastogi (@samdoc_mamc) 's Twitter Profile Photo
Dr Sameer Rastogi
@samdoc_mamc

3 months ago

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. ascopubs.org/doi/10.1200/GO… OncoDaily JCO Global Oncology

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. ascopubs.org/doi/10.1200/GO… <a href="/oncodaily/">OncoDaily</a> <a href="/JCOGO_ASCO/">JCO Global Oncology</a>